Company Overview and News
Vedanta Resources is considering options including lay-offs for some of the 2,000 employees of its iron ore business in southwest India that was shut down by a court, two sources said, as it struggles with a series of setbacks in the country.
June 12 (Reuters) - Britain’s FTSE 100 index is seen opening up 10 points at 7,747 on Tuesday, according to financial bookmakers, with futures up 0.21 percent ahead of the cash market open.
CRTHF CRNHY VED RDL BATS 4162 TBAKY TBAKF TED
LONDON, June 11 (Reuters) - Copper prices slid on Monday as fears about output disruption at the Escondida mine in Chile receded, but worries about supplies from Vedanta’s copper smelter in India and a softer dollar provided some support.
VED SCGLF SCGLY GLE
Police are only arresting people involved in protests against a copper smelter owned by Vedanta Resources where there is videographed evidence of them indulging in "anti-social" activities, a senior Tamil Nadu minister told Reuters.
Tata Steel has joined the race for Usha Martin's Jamshedpur facility, which was put on the block to pare some of the parent's debt.
517146 500228 BHUSANSTL UHBTY JSWSTEEL USHAMART VED 500470 TTST TATASTEEL TATLY 500570 TATAMOTORS 500055 TTM
After the successful acquisition of Italy's Aferpi, and the winning bid for Monnet Ispat in the domestic market, Sajjan Jindal-led JSW Steel is looking for more distressed assets in India and overseas.
USHAMART 517146 VED 500470 TTST TATASTEEL TATLY 500228 BHUSANSTL UHBTY JSWSTEEL 500055
Mumbai: Billionaire Anil Agarwal’s Vedanta Ltd has taken over on Monday control of bankrupt company Electrosteel Steels Ltd, the former said in a regulatory filing.
ESL VED 500470 TTST TATASTEEL TATLY BHUSANSTL 533264 VEDL 500055
THOOTHUKUDI, India (Reuters) - Eleven days after police in southern India fired on protesters seeking the shutdown of a copper smelter owned by London-listed Vedanta, killing 13, residents say people suspected of involvement in the demonstrations are being targeted in a wave of arrests.
Eleven days after police in southern India fired on protesters seeking the shutdown of a copper smelter owned by London-listed Vedanta, killing 13, residents say people suspected of involvement in the demonstrations are being targeted in a wave of arrests.
Businessmen are mainly concerned with making profits. They live in a competitive world and they have to produce goods at the lowest possible cost. Their profits are determined by the payments made for the raw materials such as copper ore by the Sterilite plant in Tuticorin, cost of land, machinery and labour. The cost to the society from pollution of air and water does not enter into their calculations.
VED 532792 CAIRN CWNQY
New Delhi:The permanent closure of Vedanta Resources Plc’s copper operations in India is marginally credit negative as it will lower the company’s scale and business diversity, Moody’s Investors Service on Friday said.
New Delhi: The National Company Law Appellate Tribunal (NCLAT) on Wednesday permitted Vedanta Ltd to make an upfront payment of Rs5,320 crore to the Committee of Creditors (CoC) of debt-ridden Electrosteel Steels India Ltd, according to its approved debt resolution plan.
ESL VED 500470 TTST TATASTEEL TATLY 533264 VEDL SBAZ
LONDON, May 30 (Reuters) - Copper fell to a three-week low on Wednesday as a retreat in stock markets on worries over political turmoil in Italy kept pressure on cyclical assets, offsetting a weaker dollar.
New Delhi: Vedanta Resources Plc is working on a legal challenge to Tamil Nadu ordering a permanent shutdown of the Sterlite copper plant in Thoothukudi, but it will not proceed until tensions over the deaths of 13 people during protests last week have eased, two people told Reuters.
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
2018-06-11 - Asif
Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...
Silicon Investor Message Boards
This table lists all message boards related to LSE:VED / VEDANTA RESOURCES on message board site Silicon Investor.